Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015187 | 0.98 | LMNA (0.36) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL23015167 | 0.98 | LMNA (0.36) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL1535208 | 0.98 | LMNA (0.36) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL23014944 | 0.98 | LMNA (0.36) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL790240 | 0.92 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL16420274 | 0.87 | RAB9A (0.33) | LMNA | |
| SCHEMBL19878004 | 0.85 | RECQL (0.38) | ALDH1A1KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL4062326 | 0.84 | SELP (0.34) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL31725737 | 0.84 | RAB9A (0.38) | — | |
| SCHEMBL4053856 | 0.82 | SELP (0.37) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149479-A1 | SYNTHESIS OF MODIFIED NUCLEOSIDE TRIPHOSPHATES | ROCHE DIAGNOSTICS GMBH (DE) | 2025-07-17 | — | — | WO | disclosed |
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2025-01-30 | — | — | US | disclosed |
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2024-02-08 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2020-01-30 | — | — | US | disclosed |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180237422-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3270926-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-8921328-B2 | E-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130331350-A1 | E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130089884-A1 | Protein Modification from the Oxidation of Clickable Polyunsaturated Fatty Acid Analogs | Life Technologies Corporation (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012037034-A1 | E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20110059982-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059982-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2250170-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Merck Patent GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009112139-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | MERCK PATENT GMBH, (DE) | 2009-09-17 | — | — | WO | disclosed |
| US-4877779-A | CALCIUM CHANNEL BLOCKERS; TREATMENT OF IRRITABLE BOWEL SYNDROME | MARION LABORATORIES, INC. (US) | 1989-10-31 | — | — | US | disclosed |
| US-4602006-A | Ynenolactone protease inhibitors | SYNTEX (U.S.A.) INC. (US) | 1986-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237422-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | ALDH1A1 608/4885KDM4E 2467/4885CYP1A2 256/4885 |
| US-20130331350-A1 | E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | ALDH1A1 891/4885KDM4E 3712/4885CYP1A2 2735/4885 |
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | ALDH1A1 2622/4885KDM4E 2810/4885CYP1A2 1850/4885 |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | ALDH1A1 608/4885KDM4E 2467/4885CYP1A2 256/4885 |
| US-20130089884-A1 | Protein Modification from the Oxidation of Clickable Polyunsaturated Fatty Acid Analogs | FASN, ACSL6, FADS1 | ALDH1A1 814/4885KDM4E 3051/4885CYP1A2 3334/4885 |
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | ALDH1A1 2622/4885KDM4E 2810/4885CYP1A2 1850/4885 |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | ALDH1A1 2622/4885KDM4E 2810/4885CYP1A2 1850/4885 |
| US-20110059982-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, PNMT, GRIN2C | ALDH1A1 1711/4885KDM4E 1530/4885CYP1A2 103/4885 |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | GPR55, GPR65, GPR35 | ALDH1A1 2622/4885KDM4E 2810/4885CYP1A2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.